The High Authority for Health (HAS) specifies its vaccination strategy to be implemented around a confirmed case of monkeypox for those who were vaccinated in childhood against smallpox and children.
Cases of monkeypox continue to climb in France. This Monday, June 20, the High Authority for Health (HAS) unveiled details concerning the vaccination of certain populations. After the recommendation in May concerning the vaccination of adults with high-risk contacts, the HAS was seized by the Ministry of Health to specify the vaccination strategy to be implemented around children and first-timers (people vaccinated in their childhood against smallpox).
#Communiqué | Entry by @sante_gouv HAS specifies the vaccination strategy to be implemented around a confirmed case of #Monkeypox for those who were vaccinated in childhood against smallpox and children.
? https://t.co/q7lIVYZkyx pic.twitter.com/VtWCjoDqbd
– High Authority for Health (@HAS_sante) June 20, 2022
For first-timers, HAS has recommended the administration of a single dose of the Imvanex vaccine (Bavarian Nordic) for at-risk contact persons who received smallpox vaccination with a first-generation vaccine before 1980. In the case where the contact persons at risk are immunocompromised, previous vaccination with another smallpox vaccine does not modify the schedule initially recommended in this population, i.e. three doses of Imvanex.
The Imvanex vaccine is only authorized in adults, but several studies concerning other vaccines using the same platform as Imvanex have demonstrated good tolerance in children over four months old, according to the HAS. She thus recommended that reactive vaccination of child contacts at risk “could be considered, to protect children exposed and possibly more likely to develop severe forms of the disease, in particular the most fragile and the immunocompromised”.
Read also :
Monkey pox: vaccination has started in some countries including France
But without clinical data on the safety of third-generation vaccines, the HAS recommended that the vaccination of minors “be considered on a case-by-case basis, by specialists only and after a strict assessment of the benefits and risks for the minor concerned”.